Skip to main content
Clinical Trials/NCT00957177
NCT00957177
Completed
Phase 3

Effect of Preoperative Pregabalin Administration on the Postoperative Opioid Consumption in Patients Undergoing Nephrectomy

Medical University of Graz1 site in 1 country20 target enrollmentApril 2009

Overview

Phase
Phase 3
Intervention
Placebo
Conditions
Postoperative Pain
Sponsor
Medical University of Graz
Enrollment
20
Locations
1
Primary Endpoint
postoperative opioid consumption
Status
Completed
Last Updated
14 years ago

Overview

Brief Summary

Pregabalin 300mg or placebo are administered 1 hour preoperatively in patients undergoing elective nephrectomy. Postoperatively, patients receive a patient controlled analgesia device for self delivering opioids. Morphine consumption in the first 48 hours is documented.

Hyperalgesia is measured by von-Frey-Filaments.

Registry
clinicaltrials.gov
Start Date
April 2009
End Date
December 2010
Last Updated
14 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Medical University of Graz

Eligibility Criteria

Inclusion Criteria

  • patients undergoing elective nephrectomy

Exclusion Criteria

  • contraindication against pregabalin
  • creatinine \> 2.0 mg/dl
  • GGT \>165, AST \>105, ALT \>135
  • peptic Ulcus
  • haemorrhagic diathesis
  • angina pectoris, myocardial infarction
  • bronchial asthma
  • opioid abuse

Arms & Interventions

Placebo

Placebo

Intervention: Placebo

Pregabalin group

Receiving 300mg pregabalin preoperative

Intervention: Pregabalin

Outcomes

Primary Outcomes

postoperative opioid consumption

Time Frame: 48 hours

Study Sites (1)

Loading locations...

Similar Trials